BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 31672842)

  • 1. Natural Killer Cell-Derived Vesicular miRNAs: A New Anticancer Approach?
    Fabbri M
    Cancer Res; 2020 Jan; 80(1):17-22. PubMed ID: 31672842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Professional killers: The role of extracellular vesicles in the reciprocal interactions between natural killer, CD8+ cytotoxic T-cells and tumour cells.
    Del Vecchio F; Martinez-Rodriguez V; Schukking M; Cocks A; Broseghini E; Fabbri M
    J Extracell Vesicles; 2021 Apr; 10(6):e12075. PubMed ID: 33815694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer extracellular vesicles as novel regulators of NK cell response.
    Soriani A; Vulpis E; Cuollo L; Santoni A; Zingoni A
    Cytokine Growth Factor Rev; 2020 Feb; 51():19-26. PubMed ID: 31837917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural Killer Cell-Derived Extracellular Vesicles: Novel Players in Cancer Immunotherapy.
    Wu F; Xie M; Hun M; She Z; Li C; Luo S; Chen X; Wan W; Wen C; Tian J
    Front Immunol; 2021; 12():658698. PubMed ID: 34093547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy.
    Devillier R; Chrétien AS; Pagliardini T; Salem N; Blaise D; Olive D
    J Leukoc Biol; 2021 Jun; 109(6):1071-1088. PubMed ID: 32991746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteome Analysis of Human Natural Killer Cell Derived Extracellular Vesicles for Identification of Anticancer Effectors.
    Choi JW; Lim S; Kang JH; Hwang SH; Hwang KC; Kim SW; Lee S
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33182448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
    Hu W; Wang G; Huang D; Sui M; Xu Y
    Front Immunol; 2019; 10():1205. PubMed ID: 31214177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming.
    Zhu L; Kalimuthu S; Oh JM; Gangadaran P; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
    Biomaterials; 2019 Jan; 190-191():38-50. PubMed ID: 30391801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human NK cells: From surface receptors to clinical applications.
    Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
    Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.
    Cifaldi L; Di Santo J; Olive D
    Front Immunol; 2020; 11():1132. PubMed ID: 32612604
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting natural killer cells in cancer immunotherapy.
    Guillerey C; Huntington ND; Smyth MJ
    Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
    Gaggero S; Witt K; Carlsten M; Mitra S
    Front Immunol; 2020; 11():621225. PubMed ID: 33584718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.
    Barrow AD; Colonna M
    Semin Immunol; 2017 Jun; 31():30-36. PubMed ID: 28935344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK cells to cure cancer.
    Di Vito C; Mikulak J; Zaghi E; Pesce S; Marcenaro E; Mavilio D
    Semin Immunol; 2019 Feb; 41():101272. PubMed ID: 31085114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Natural Killer Cells for Tumor Immunotherapy.
    Zhang C; Hu Y; Shi C
    Front Immunol; 2020; 11():60. PubMed ID: 32140153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional and metabolic targeting of natural killer cells to solid tumors.
    Wang J; Matosevic S
    Cell Oncol (Dordr); 2020 Aug; 43(4):577-600. PubMed ID: 32488848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural Killer Cell-Derived Extracellular Vesicles as a Promising Immunotherapeutic Strategy for Cancer: A Systematic Review.
    Chan AML; Cheah JM; Lokanathan Y; Ng MH; Law JX
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.